Table 3.

Hazard ratios of cancer‐specific deaths in males by cancer site, race, and diabetes status in SEER‐Medicare, 66+ y diagnosed in 2000‐2011

Cancer site	Race	Diabetes status	N	HR	95% CI	P‐values
Bladder	White	Without diabetes	32 207	Ref	~	<.0001
		With diabetes	10 426	1.17	1.14‐1.20
	Black	Without diabetes	1107	1.30	1.21‐1.39
		With diabetes	515	1.30	1.17‐1.44
Colon/Rectum	White	Without diabetes	39 552	Ref	~	<.0001
		With diabetes	12 462	1.16	1.13‐1.19
	Black	Without diabetes	3485	1.24	1.19‐1.29
		With diabetes	1464	1.27	1.20‐1.35
Hodgkin lymphoma	White	Without diabetes	683	Ref	~	.7236
		With diabetes	228	0.98	0.83‐1.17
	Black	Without diabetes	38	0.89	0.60‐1.32
		With diabetes	15	0.76	0.44‐1.30
Liver	White	Without diabetes	3252	Ref	~	.0004
		With diabetes	2611	1.03	0.98‐1.09
	Black	Without diabetes	411	1.23	1.11‐1.36
		With diabetes	211	1.17	1.01‐1.34
Myeloma	White	Without diabetes	5302	Ref	~	.0003
		With diabetes	1595	1.10	1.03‐1.17
	Black	Without diabetes	784	1.11	1.02‐1.20
		With diabetes	342	1.19	1.06‐1.34
Non‐Hodgkin lymphoma	White	Without diabetes	15 336	Ref	~	<.0001
		With diabetes	4696	1.24	1.19‐1.29
	Black	Without diabetes	621	1.29	1.18‐1.41
		With diabetes	248	1.53	1.33‐1.76
Pancreas	White	Without diabetes	8441	Ref	~	<.0001
		With diabetes	4944	1.05	1.02‐1.09
	Black	Without diabetes	788	1.13	1.05‐1.22
		With diabetes	468	1.17	1.07‐1.29
Prostate	White	Without diabetes	141 215	Ref	~	<.0001
		With diabetes	30 745	1.22	1.20‐1.25
	Black	Without diabetes	17 232	1.20	1.17‐1.22
		With diabetes	5975	1.37	1.32‐1.42
Stomach	White	Without diabetes	6465	Ref	~	.0076
		With diabetes	2384	1.04	0.99‐1.09
	Black	Without diabetes	962	1.12	1.04‐1.20
		With diabetes	361	1.09	0.98‐1.22

CI, confidence interval; HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.

All models adjusted for age, stage, comorbidities, and treatment.